2cureX (2CUREX) Investor update summary

Strategic direction and platform development

• Transitioning to a broader functional precision medicine platform, emphasizing tumor preservation and storage as a key step in cancer diagnostics and treatment pathways.

• Focus on building an end-to-end solution, integrating early diagnostics, genomics, functional testing, and treatment.

• Expanding ecosystem includes patient access, tumor logistics, laboratory partnerships, and decentralized oncology testing.

• Partnerships with PreComb Therapeutics and StoreMyTumor enhance pharma collaborations and U.S. market entry.

• Infrastructure build-out aims to support patient journey, decentralized testing, and U.S. expansion.

Competitive landscape and regulatory advantage

• Holds a two to three-year lead over industry competitors, with strong IP and regulatory approvals (IVDR certification).

• Major competition comes from laboratory-developed tests in hospitals, but these are limited to clinical trial settings.

• Planned hospital placements will allow daily clinical use, bypassing the need for clinical trials.

• Market penetration for this technology remains extremely low, with competition seen as validation and market education.

Data, commercial value, and recurring revenue

• Access to tumor tissue and data generation is a key value driver, drawing parallels to Foundation Medicine's acquisition by Roche.

• Partnership with StoreMyTumor enables both immediate patient options and long-term data-driven insights for stakeholders.

• The business model is designed for recurring downstream revenue through a shared diagnostic platform.